230 related articles for article (PubMed ID: 27434392)
1. Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis.
Minard LV; Corkum A; Sketris I; Fisher J; Zhang Y; Saleh A
PLoS One; 2016; 11(7):e0158608. PubMed ID: 27434392
[TBL] [Abstract][Full Text] [Related]
2. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
3. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
Zhou YY; Zhu GQ; Wang Y; Zheng JN; Ruan LY; Cheng Z; Hu B; Fu SW; Zheng MH
Oncotarget; 2016 Apr; 7(16):21753-62. PubMed ID: 26943041
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
5. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
6. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Hoffman KB; Kraus C; Dimbil M; Golomb BA
PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Zhou Z; Rahme E; Abrahamowicz M; Tu JV; Eisenberg MJ; Humphries K; Austin PC; Pilote L
CMAJ; 2005 Apr; 172(9):1187-94. PubMed ID: 15851712
[TBL] [Abstract][Full Text] [Related]
8. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Andrews TC; Ballantyne CM; Hsia JA; Kramer JH
Am J Med; 2001 Aug; 111(3):185-91. PubMed ID: 11530028
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies.
Variya BC; Patel SS; Trivedi JI; Gandhi HP; Rathod SP
Eur J Pharmacol; 2015 Oct; 764():283-291. PubMed ID: 26169562
[TBL] [Abstract][Full Text] [Related]
10. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
[TBL] [Abstract][Full Text] [Related]
13. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
14. Statin trials in progress: unanswered questions.
Davidson MH
Curr Atheroscler Rep; 2001 Jan; 3(1):9-13. PubMed ID: 11123842
[TBL] [Abstract][Full Text] [Related]
15. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Karie S; Launay-Vacher V; Deray G; Isnard-Bagnis C
Presse Med; 2006 Feb; 35(2 Pt 1):219-29. PubMed ID: 16493350
[TBL] [Abstract][Full Text] [Related]
16. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials.
Sahebkar A; Serban C; Ursoniu S; Mikhailidis DP; Undas A; Lip GY; Bittner V; Ray K; Watts GF; Hovingh GK; Rysz J; Kastelein JJ; Banach M;
Thromb Haemost; 2016 Mar; 115(3):520-32. PubMed ID: 26632869
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
Yu JM; Chen WM; Shia BC; Wu SY
Eur J Clin Pharmacol; 2023 May; 79(5):687-700. PubMed ID: 37010535
[TBL] [Abstract][Full Text] [Related]
18. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
19. Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer.
Huang BZ; Chang JI; Li E; Xiang AH; Wu BU
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040693
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
